Analyst upgrades:

• Toll Brothers (NYSE: TOL) was upgraded to Buy at Citigroup. The firm views the recent sell-off in home building stocks as a buying opportunity and thinks Toll Brothers offers the best risk/reward in its coverage universe. Citi keeps a $23 price target on the stock.
• Kellogg (NYSE: K) was upgraded to Buy from Hold at Citigroup following the Q3 results, as it believes the company's reduced spending and share buyback will serve as catalysts. The firm raised its price target on shares to $63 from $50.
• Rogers Communications (NYSE: RCI) and Telus (NYSE: TU) were upgraded to Outperform from Sector Perform at RBC Capital, which said the CRTC unexpectedly denied Globalive's wireless application. The analyst said Globalive was potentially the biggest of new wireless competitors and the decision removes a big threat to the group. Rogers price target was raised to $40 from $33; Telus to $44 from $36.
• Stanley (NYSE: SXE) was upgraded at Wells Fargo to Outperform from Market Perform after the company reported better-than-expected Q3 results and raised its FY10 guidance.
• Texas Instruments (NYSE: TXN) was upgraded at Bernstein to Outperform from Market Perform. The analyst believes Texas Instruments' core business earnings power is underappreciated and valuation is attractive. Target raised to $30 from $28.

Analyst upgrades:

• Canaccord upgraded Imperial Oil (NYSE: IMO) to Buy from Speculative Buy following an increase in crude oil forecast.
• BT Group (NYSE: BT) was upgraded to Outperform from Market Perform at Bernstein.
  
• Novartis (NYSE: NVS) was upgraded to Overweight from Neutral at JP Morgan.
  
• CommVault (NASDAQ: CVLT) was upgraded to Neutral from Sell at Goldman.
  
• AvalonBay (NYSE: AVB) was upgraded to Buy from Hold at Sandler O'Neill.

Analyst upgrades:

• Jefferies upgraded NeuStar (NYSE:NSR) to Hold from Underperform on valuation following the recent weakness and raised their target price to $15 from $12.
  
• Oppenheimer upgraded Adobe Systems (NASDAQ:ADBE) to Outperform from Perform on valuation as they believe the recent pullback has created an attractive entry point into the name. The firm has a $27 target on the stock.
  
• UBS upgraded Pfizer (NYSE:PFE) and Wyeth (NYSE:WYE) to Buy from Neutral based on valuations. Pfizer's price target remains $18 and Wyeth's was raised to $50 from $38.
• Methanex (NASDAQ:MEOH) was upgraded to Sector Outperformer from Sector Performer at CIBC.
  
• BHP Billiton (NYSE:BHP) was raised to Buy from Hold at RBS.
  
• Anadys Pharma (NASDAQ:ANDS) was upgraded to Buy from Neutral at Piper Jaffray.

Analyst upgrades:

• Citigroup upgraded shares of Ball (NYSE: BLL) to Buy from Hold and raised its target to $45 from $41 as they believe recent capacity closures will be positive for beverage can operating rates.
  
• Deutsche Bank upgraded Rio Tinto (NYSE: RTP) to Buy from Hold on valuation and the company's plans to preserve cash.
• ThinkPanmure upgraded Intel (NASDAQ: INTC) to Accumulate from Sell and raised its target to $17 from $12 citing trough earnings in 2009 and lowered expectations.
• Viacom B (NYSE: VIA.B) was added to Goldman's Conviction Buy List.
  
• Telefonica (NYSE: TEF) was upgraded to Outperform from Neutral at Credit Suisse.
  
• Onyx Pharma (NASDAQ: ONXX) was raised to Overweight from Neutral at JP Morgan.

Analyst downgrades:

MOST NOTEWORTHY: The coal sector, independent refiners and Alexion Pharmaceuticals were today's noteworthy downgrades:

• Goldman downgraded the coal sector to Cautious from Neutral, citing valuations and expectations for lower coal prices. The firm downgraded CONSOL Energy (NYSE: CNX) Peabody Energy (NYSE: BTU) to Neutral from Buy and Arch Coal (NYSE: ACI) to Sell from Neutral.
  
• Lehman downgraded independent refiners, including Alon USA Energy (NYSE: ALJ), to Negative from Neutral and continues to believe that 2H07 marked an inflection point for U.S. refiners, which are transitioning from a multiyear up-cycle into a new downtrend.
  
• Alexion Pharmaceuticals (NASDAQ: ALXN) was lowered to Market Perform from Outperform at Wachovia following the company's Q4 results, as they believe management's revenue guidance represents a best-case scenario.

OTHER DOWNGRADES:

• Lehman lowered Bayer (OTC: BAYRY) to Equal Weight from Overweight and Whole Foods (NASDAQ: WFMI) to Underweight from Equal Weight.

Alexion Pharm (NYSE: ALXN) is a product developer of anti-inflammatory therapeutics, primarily for hematological and cardiovascular discords, autoimmune diseases and cancer. ALXN is recently up $1.35 to $73.81 on unconfirmed & renewed takeover chatter. ALXN has a market cap of $2.7 billion, with long-term debt of $176 million. ALXN had June 2007 total quarterly revenue of $9.6 million. ALXN November option implied volatility of 57 is above its 26-week average of 41 according to Track Data, suggesting larger risks.

Sterlite (NYSE: SLT), a non-ferrous metals and mining company based in India, is recently up $2.47 to $22.10. SLT call option volume of 3,868 contracts compares to put volume of 521 contracts. SLT November option implied volatility of 84 is above its six-week average of 51 according to Track Data, suggesting larger risk.

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Monday March 19

• Nortel Networks Corporation (NYSE: NT) to report Q4 earnings; conference call at 8:30am. Analysts will be focused on Nortel's Mobility enterprise solutions revenue, as well as new business opportunities and clients.

Tuesday March 20

• Two well known technology companies to report -- Adobe Systems Inc's (NASDAQ: ADBE) Q1 conference call is at 5pm, Oracle Corporation's (NASDAQ: ORCL) Q3 conference call is at 5pm.

• PDUFA Date for Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) Solaris, a treatment for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.

Wednesday March 21

• The International Trade Commission will hold a public hearing on the Patent Infringement case between Broadcom Corporation (NASDAQ: BRCM) and Qualcomm Inc (NASDAQ: QCOM) at 9:30am.

• Starbucks Corporation (NASDAQ: SBUX) will hold a shareholder meeting at 1pm in Seattle. Ferris Baker Watts believes the meeting will alleviate some concerns over a previously leaked internal memo written by CEO Howard Schultz that had a cautious tone.

Thursday March 22

• Nike Inc (NYSE: NKE) to report Q3 earnings; conference call at 5pm. Along with performance by region [North America, Europe, Asia], and evaluation of pricing pressures, analysts will review Nike's revised Air Force One product performance –- deemed a catalyst for growth moving forward .

Friday March 23

• Freddie Mac (NYSE: FRE) to report Q4 earnings; conference call at 8:30am.
• Virginia District Court to hold injunction hearing between Vonage Holdings Corp (NYSE: VG) and Verizon Communications Inc (NYSE: VZ).

MOST NOTEWORTHY: In addition to Genomic Health (GHDX) and Intercontinental Hotels Group (IHG), airliners Continental Airlines (CAL) and ExpressJet Holdings (XTJ) were some of today's most notable initiations:

• RBC Capital Markets started Genomic Health Inc (NASDAQ: GHDX) with an Underperform rating, with a $17 target. The firm views shares as fairly valued and believes competitive noise and FDA concerns will weigh on shares.

• HSBC started Intercontinental Hotels (NYSE: IHG) with an Overweight rating, believing asset sales and stronger than expected room growth could prove near-term positive catalysts.

• Soliel started both Continental Airlines (NYSE: CAL) and ExpressJet Holdings Inc (NYSE: XJT) with Sell ratings.

OTHER INITIATIONS:

• William Blair started Alexion Pharmaceuticals (NASDAQ: ALXN) with an Outperform rating. They believe Alexion's lead compound, Soliris, is the key driver of shareholder value, and they believe the company is well positioned to receive final FDA approval.

• Bear Stearns initiated Baldor Electric Company (NYSE: BEZ) with an Outperform rating.

• RBC initiated Hologic, Inc (NASDAQ: HOLX) with an Outperform rating.

• Citigroup started GMarket Inc (NASDAQ: GMKT) with a Sell rating and $18 target, citing valuation.

• Drew Industries, Inc (NYSE: DW) was initiated with a Buy rating and $35 target at Ferris Baker Watts.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).